IngredientsScopoletin, also known as 6-methoxy-7-hydroxycoumarin, is one of the naturally occurring coumarins commonly found in many edible plants and plays an important role in human health. Its systematic IUPAC name is 7-hydroxy-6-methoxy-2H-chromen-2-one. Scopoletin is a hydroxycoumarin with a molecular weight of 192.7 g/mol and a melting point of 204°C–206°C; the empirical formula of the compound is C10H8O4. It is slightly soluble in water or cold ethanol, soluble in hot ethanol or hot acetic acid, easily soluble in chloroform, and almost insoluble in benzene.
Scopoletin (6-methoxy-7-hydroxycoumarin) is a phytoalexin — a low molecular weight compound biosynthesized in response to microbial attack over the plant. Scopoletin is highly fluorescent when dissolved in DMSO or water and is regularly used as a fluorimetric assay for the detection of hydrogen peroxide in conjunction with horseradish peroxidase. When oxidized, its fluorescence is strongly suppressed.
Scopoletin belongs to the broader class of simple hydroxycoumarins, a subclass of benzopyranones derived from the phenylpropanoid biosynthetic pathway. Its closest structural relatives include scoparone (6,7-dimethoxycoumarin), esculetin (6,7-dihydroxycoumarin), and its glucoside form scopolin. Scoparone is biosynthetically derived from esculetin, scopoletin, and isoscopoletin through methoxylation of one or two hydroxyl groups at the C-6 and C-7 positions.
Scopoletin is a coumarin found in the root of plants in the genus Scopolia such as Scopolia carniolica and Scopolia japonica, in chicory, in Artemisia scoparia, in the roots and leaves of stinging nettle (Urtica dioica), in the passion flower, in Brunfelsia, in Viburnum prunifolium, in Solanum nigrum, in Datura metel, in Mallotus resinosus, and in Kleinhovia hospita. It can also be found in fenugreek, vinegar, some whiskies and in dandelion coffee.
Beyond these well-known sources, scopoletin has been identified across a wide taxonomic range. Scopoletin has been analyzed in Morinda citrifolia L., Fraxinus rhynchophylla Hance, Torilis radiata, Brunfelsia hopeana Benth., and Canarium patentinervium Miq. Additional documented sources include the heartwood of Acer nikoense, the flowers of Tilia cordata, the heartwood of Acer nikoense Miq., and the inner shell of the nut of Castanea crenata.
Scopoletin has been identified at different levels of concentrations across plant parts, in many different species and plant families. Its presence spans botanical families including Asteraceae and many others, including Rubiaceae, Solanaceae, Adoxaceae, Apiaceae, and Convolvulaceae, among others. The compound occurs in roots, leaves, bark, fruits, flowers, and heartwood depending on the species, and concentrations can vary substantially with plant age, tissue type, and environmental stressors.
Morinda citrifolia, commonly referred to as noni, a Polynesian medicinal plant with over 2000 years of traditional use, has garnered global interest for its rich repertoire of antioxidant phytochemicals, including flavonoids (kaempferol, rutin), iridoids (aucubin, asperulosidic acid, deacetylasperulosidic acid, asperuloside), polysaccharides (nonioside A), and coumarins (scopoletin).
Scopoletin is encountered in commerce and research in several forms. As a pure compound, it is available as a white-to-off-white crystalline powder used in laboratory research and pharmaceutical development. In the context of dietary supplements, it is most commonly consumed indirectly as a constituent of Morinda citrifolia (noni) fruit juice or fruit powder preparations, or as part of standardized herbal extracts of plants such as Artemisia species or Viburnum bark. The bark of both Viburnum opulus and Viburnum prunifolium species is used medicinally and may be decocted, tinctured, or encapsulated as crude herb.
Scopolin — the β-D-glucopyranoside (glucoside) of scopoletin — is the storage form found in many plants and is hydrolyzed to release free scopoletin in the plant or upon metabolic processing. Scopolin is a glucoside of scopoletin found in tobacco and Duboisia myoporoides.
Noni (Morinda citrifolia) is included in the listings of traditional medicines of Native Hawaiians, other Pacific Islanders, and Asian populations, and has been used to treat various diseases for centuries. Scopoletin is one of the principal bioactive coumarins identified in noni. Noni, with all its different parts (fruit, leaf, bark, root, flower, and seed), has been used in traditional medicine for treatment and prevention of a variety of illnesses in its native countries, reflecting both the ecological conditions of specific locations and the accumulated traditional knowledge transmitted through generations; noni is integrated into folk medicine as a multipurpose therapy. Traditional use of noni fruit includes the prevention of indigestion, nausea, vomiting, and constipation, as well as its antibacterial and antifungal effects.
Scopolin (the glucoside of scopoletin) was usually used for rheumatic arthritis therapy in traditional Chinese medicine. Artemisia scoparia (virgate wormwood, or Yin Chen Hao), one of the most important scopoletin-containing plants in the East Asian pharmacopeia, has been used for centuries in Traditional Chinese Medicine (TCM) for conditions related to the liver and biliary system, including jaundice and hepatic disorders. Published studies have revealed pharmacological effects attributed to verified bioactive compounds including scoparone, scopoletin, capillarisin, capillin, and chlorogenic acids; these commonly extracted bioactive compounds induce pharmacological effects, including anti-inflammatory, antioxidant, choleretic, antisteatotic, antidiabetic, and antitumor activities.
Cramp bark (Viburnum opulus) is included in the British Herbal Pharmacopoeia and is used by herbalists in the United Kingdom for miscarriage prevention; it is thought that at least four active substances, including scopoletin and aesculetin, which have been identified, have uterine spasmolytic activity. Viburnum opulus contains hydroquinones, coumarins, and tannins, whereas Viburnum prunifolium's primary constituents include coumarins, biflavones, and phenolic acids; both Viburnum species treat dysmenorrhea.
The use of Viburnum prunifolium (black haw) bark was adopted by 19th-century Eclectic physicians. A published report from the American Gynecological Society in 1876 records that a practitioner had used viburnum during the past ten years in a great number of cases of threatened abortion and recommended it as the most efficacious remedy for this trouble, especially in cases where abortion had become habitual with a woman; he also recommended it as a valuable therapeutic agent in symptomatic disorders incident to pregnancy, and found it extremely useful in uterine disorders characterized by loss of blood such as menorrhagia and dysmenorrhea.
Scopoletin from the species Viburnum prunifolium and Angelica (essential oil extracted from the roots) has hypotensive and spasmolytic properties — able to inhibit the spastic contraction of smooth gastrointestinal and genitourinary muscle.
Argyreia speciosa (vridhadaraka), meaning antiaging, has been mentioned in Ayurvedic material medica for its medicinal properties such as rheumatism, hepatoprotective, immunomodulatory, antioxidant, anti-inflammatory activity, and neurological disorders. Scopoletin is among the most abundant phytoconstituents identified in this plant. Scopoletin has been used as an antibacterial and antifungal compound in traditional medicine.
In Thailand, dried unripe noni fruit prepared as an aqueous decoction has been used as a traditional remedy for gastrointestinal complaints. A study evaluated the effect of dried mature unripe Morinda citrifolia L. (Rubiaceae) fruit in an aqueous extract preparation as used in Thai traditional medicine; the powder of dried mature unripe noni fruit was boiled in water until it became a sticky paste and was then dried into a powder by lyophilization.
Scopoletin has modifications in its benzene ring, and genetic studies in Arabidopsis thaliana support that scopoletin is biosynthesized from the phenylpropanoid pathway via ortho-hydroxylation of cinnamate, ρ-coumarate, caffeate, and ferulate. The phenylpropanoid pathway serves as a starting point for the production of many important compounds, including lignans, flavonoids, and coumarins; in the very first step of the phenylpropanoid pathway, phenylalanine ammonia-lyase (PAL; EC 4.3.1.5) catalyses the deamination of phenylalanine to yield trans-cinnamic acid; later, cinnamate-4-hydroxylase (C4′H; EC 1.14.13.11) catalyses the hydroxylation of cinnamate to yield ρ-coumarate.
The feruloyl CoA intermediate is subjected to ortho-hydroxylation catalysed by feruloyl CoA-6′-hydroxylase (F6′H; EC 1.14.11.61), which then causes the 6′-hydroxyferuloyl-CoA to undergo trans-cis spontaneous isomerization and non-enzymatic lactonization to form scopoletin. Some studies revealed that mutation in the f6′h1 gene responsible for F6′H extremely reduced the fluorescence signal of scopoletin in A. thaliana roots, indicating that F6′H is a 2-oxoglutarate-dependent dioxygenase essential and specific for scopoletin synthesis in A. thaliana.
The metabolic pathway for scopoletin biosynthesis involves multiple types of chemical reactions catalyzed by the following catalytic enzymes: tyrosine ammonia lyase (TAL), phenylalanine ammonia lyase (PAL), 4-coumarate CoA ligase (4CL), feruloyl-CoA synthase (FCS), cinnamate-4-hydroxylase (C4H), coumarate-3-hydroxylase (C3H), feruloyl-CoA 6′-hydroxylase (F6'H), coumarin synthase (COSY), scopoletin 8-hydroxylase (S8H), caffeoyl-CoA O-methyltransferase (CCoAOMT), and the cytochrome P450 family B2 subfamily C polypeptide 4 enzyme (CYP82C4).
The resulting coumarin aglycones can be modified by a set of UDP-glucose-dependent glucosyltransferases to result, for example, in scopolin or esculin, the most prominent soluble coumarins in plants.
Scopoletin functions ecologically as a phytoalexin — a compound produced by plants in response to pathogen attack. Comparative transcriptional and metabolic profiling of Arabidopsis revealed induction of phenylpropanoid metabolism-associated genes in both species, but activation of scopoletin biosynthesis only in the resistant non-host; scopoletin is a coumarin and an antioxidant, and in vitro experiments disclosed fungistatic activity of scopoletin against Phakopsora pachyrhizi, associated with reduced accumulation of reactive oxygen species (ROS) in fungal pre-infection structures.
Scopoletin is an inhibitor of various enzymes, including choline acetyltransferase, acetylcholinesterase (AChE), aldose reductase, γ-aminotransferase (IC50 = 10.57 μM), monoamine oxidase, quinone oxidoreductase, and inducible nitric oxide synthase (iNOS).
Scopoletin scavenges xanthine/xanthine oxidase-generated superoxide anions in a dose-dependent manner while xanthine oxidase activity is maintained, and enhances the activity of endogenous antioxidant enzymes, such as superoxide dismutase (SOD), catalase, and glutathione (GSH).
Mechanisms of anti-inflammatory action include the suppression of T-cells, downregulation of inflammation-related genes, and inhibition of pro-inflammatory cytokine production. In vitro studies showed that scopoletin inhibited proinflammatory cytokine secretion from RAW 246.7 and HMC-1 cell lines. In the context of liver disease, in alcohol-fed rats, scopoletin regulates AMPK and the toll-like receptor 4 (TLR4)/myeloid differentiation major response gene 88 (MyD88)/NF-κB pathway.
Scopoletin, investigated on 3T3-L1 cells, was found to have significant antidiabetic action; it significantly upregulated intracellular glucose uptake by expressing GLUT4 on the plasma membrane in 3T3-L1 adipocytes; the increase in GLUT4 expression on plasma promoted the phosphorylation of protein kinase B, AMPK, and also activation of PI3K; these effects of scopoletin were confirmed by treatment with the PI3K inhibitor wortmannin and the AMPK inhibitor compound C.
The antitumor activity of scopoletin may result from its anti-proliferation, anti-migration, pro-apoptotic, anti-invasion, and anti-angiogenic inhibition of multiple drug resistance, regulation of the mitogen-activated protein kinase (MAPK) and PI3K/AKT/mTOR pathways, and its effect on cell cycle arrest. Microarray-based RNA expression profiling of the NCI cell line panel showed that cellular response of scopoletin did not correlate to the expression of ATP-binding cassette (ABC) transporters as classical drug resistance mechanisms (ABCB1, ABCB5, ABCC1, ABCG2), nor to the expression of the oncogene EGFR or the mutational status of the tumor suppressor gene TP53; however, mutations in the RAS oncogenes and the slow proliferative activity in terms of cell doubling times significantly correlated with scopoletin resistance.
Scopoletin remarkably prevents acid reflux esophagitis production, with a similar efficiency to that of standard anti-secretory agents (ranitidine and lansoprazole) through its anti-inflammatory and anti-secretory attributes, such as its pro-kinetic activity, which can accelerate gastric emptying and intestinal transit. The potential mechanism is partially ascribed to the active component stimulating the 5-HT4 receptor.
Scopoletin scavenges xanthine/xanthine oxidase-generated superoxide anions in a dose-dependent manner and inhibits xanthine oxidase, maintains mitochondrial functioning to reduce ROS amounts. Hypouricemic action of scopoletin arises from xanthine oxidase inhibition and uricosuric activity.
Important framing note: The overwhelming majority of evidence on scopoletin's pharmacological activities derives from in vitro (cell-based) and in vivo (animal) studies. There are no published randomized controlled clinical trials examining isolated scopoletin as a single agent in human populations. Human evidence, where it exists, pertains almost exclusively to whole-plant preparations (most commonly noni juice) in which scopoletin is one of many active constituents, making it impossible to attribute effects specifically to scopoletin.
Summary of evidence: In vitro and animal studies; no human trials on isolated scopoletin.
Scopoletin is indicated to have antimicrobial, anticancer, anti-inflammation, anti-angiogenesis, anti-oxidation, antidiabetic, antihypertensive, hepatoprotective, and neuroprotective properties and immunomodulatory effects in both in vitro and in vivo experimental trials.
Scopoletin and isoscopoletin from fruits of Morinda citrifolia showed mild activity against 5-LO and 15-LO (lipoxygenase) and COX-2 enzymes. In animal models, scopoletin has been shown to suppress key inflammatory mediators including NF-κB, TNF-α, IL-6, and prostaglandins. The evidence at this level is consistent but remains preclinical. No well-designed human clinical trials have evaluated isolated scopoletin for any inflammatory condition.
Summary of evidence: In vitro and animal studies; consistent findings, no human trials on isolated scopoletin.
Scopoletin is a coumarin and an antioxidant. Mechanistic studies demonstrate free radical scavenging, superoxide anion quenching, and enhancement of endogenous antioxidant enzyme activity (SOD, catalase, GSH). These findings are consistent across multiple laboratory models but have not been translated into controlled human trials on scopoletin as an isolated agent.
Summary of evidence: In vitro and animal studies; some bioinformatic analyses; no human clinical trials on isolated scopoletin.
Scopoletin shows anti-proliferative action on BW5147 murine lymphoma cells and MCF-7 human adenocarcinoma cells. It exerts anticancer effects on human cervical cancer cell lines by inducing apoptosis and cell cycle arrest and inhibiting cell invasion and the PI3K/AKT signaling pathway. It is indicated to play a role in triggering cell cycle arrest and increasing apoptosis in PC3 cells via activation of caspase-3.
Three compounds: asperulosidic acid (an iridoid glycoside), damnacanthal (an anthraquinone) and scopoletin (a coumarin), have in vitro cellular/molecular effects possibly relevant to the inhibition of cancer development and progression. This finding, referenced in a noni-focused clinical trial protocol, underscores that current cancer-relevant evidence for scopoletin is mechanistic and in vitro. Evidence strength is weak for human application.
Summary of evidence: In vitro and in silico studies; no human trials on isolated scopoletin.
A study evaluates the disease-modifying potential of scopoletin against multiple factors associated with Alzheimer's disease (AD) such as cholinesterase enzymes, Aβ peptides, and neuroprotective properties against Aβ- and H2O2-induced cytotoxicity under in vitro conditions. Key quantified findings from this study: the neuroprotective potential of scopoletin was found to be 69% against Aβ42-induced neurotoxicity and 73% against H2O2-induced cytotoxicity in PC12 cell culture at 40 μM final concentration; at the same concentration, scopoletin inhibited Aβ42 fibril formation up to 57%; the IC50 concentration for AChE and BuChE enzyme inhibition by scopoletin was 5.34 and 9.11 μM, respectively.
Scopoletin shows AChE inhibitory activity in the range of 13.92%–34.18% at a concentration of 100 μg/mL. Scopoletin also exhibited anti-inflammatory, antioxidant, and antiacetylcholinesterase potential against Alzheimer's disease. These are in vitro findings; no human trials exist for this indication.
Summary of evidence: In vitro and animal studies; no human trials on isolated scopoletin.
Multiple cell-based and rodent studies demonstrate that scopoletin can enhance glucose uptake, reduce insulin resistance, and modulate key metabolic signaling pathways. It significantly upregulated intracellular glucose uptake by expressing GLUT4 on the plasma membrane in 3T3-L1 adipocytes; the increase in GLUT4 expression on plasma promoted the phosphorylation of protein kinase B, AMPK, and also activation of PI3K. Evidence is preliminary and animal/cell-based only.
Summary of evidence: Animal studies; no human trials on isolated scopoletin.
Orally administered scopoletin (0.05%, w/w) decreased lipid contents in the liver and plasma and the activities of hepatic lipogenic enzymes in alcohol plus 35% kcal high-fat diet (HFD)-induced mice. The potential mechanism for these effects was modulation of AMP-activated protein kinase (AMPK)-sterol regulatory element-binding protein 1C (SREBP-1c) pathway-mediated lipid biosynthesis. The choleretic, anti-inflammatory, and antioxidant effects that partly come from scoparone and scopoletin contributing to anti-hepatitis treatment could achieve a therapeutic window within a relatively short time. All hepatoprotective evidence is animal-level.
Summary of evidence: Animal pharmacology; limited human data only through complex noni preparations.
Scopoletin has been documented to possess vasodilatory and smooth-muscle-relaxing properties. Scopoletin from Viburnum prunifolium and Angelica has hypotensive and spasmolytic properties — able to inhibit the spastic contraction of smooth gastrointestinal and genitourinary muscle. Derivative compounds synthesized from scopoletin have also been developed as vasorelaxing agents: multiple substituted 8,8-dimethyl-8H-pyrano[2,3-f]chromen-2-ones (chromeno-coumarin hybrids) have been synthesized based on scopoletin as vasorelaxing agents. Evidence in humans is not available for isolated scopoletin.
Summary of evidence: Animal studies; no human trials on isolated scopoletin.
In rodent models, scopoletin has demonstrated the ability to lower serum uric acid via dual mechanisms. Ding et al. showed that scopoletin (100 and 200 mg/kg, i.p.) causes a significant reduction in uric acid activity associated with potassium oxonate by decreasing the serum uric acid level and enhancing urine urate. Scopoletin (200 mg/kg, p.o.) remarkably lowers the serum uric acid level of a yeast extract in potassium oxonate-induced mice; the therapeutic mechanisms are associated with inhibition of the activity of hepatic xanthine oxidase and promotion of uric acid excretion. These are animal findings.
Summary of evidence: Animal studies and one rat model study of clinical relevance; no human trials on isolated scopoletin.
An aqueous fruit extract of Morinda citrifolia (0.63–2.50 g/kg) significantly prevented the formation of acid reflux esophagitis, reduced the formation of ethanol-induced acute gastric lesions, suppressed the development of gastric lesions in response to serotonin, and accelerated the healing of acetic acid-induced chronic gastric ulcer in rats with equal potency to those obtained by standard antisecretory agents (ranitidine and lansoprazole). Pure scopoletin has similar antisecretory and antiulcer properties to that of an aqueous extract of noni, but lower prokinetic activity. Sun et al. preliminarily confirmed that scopoletin isolated from Cynachum auriculatum has an anti-functional dyspepsia effect.
Summary of evidence: In vitro studies; no human trials.
Scopoletin has attracted the attention of medicinal chemists and health professionals because of its broad range of beneficial properties, including antibacterial, antifungal, and antiparasitic activities. These have been demonstrated in cell culture and microbiological assays. No controlled human antimicrobial trials exist for isolated scopoletin.
Summary of evidence: Animal and in vitro studies; no human trials.
Scopoletin has been studied in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis. Studies indicate that scopoletin can suppress dendritic cell activation and inhibit NF-κB signaling, thereby modulating the immune response. In vitro studies showed that scopoletin inhibited proinflammatory cytokine secretion from RAW 246.7 and HMC-1 cell lines. This evidence is entirely preclinical.
The broad range of documented pharmacological activities associated with scopoletin spans antibacterial, antifungal, antiparasitic, anticancer, anti-inflammation, hepatoprotective, antihyperlipidemic, antidiabetic, neuroprotective, antioxidant, anti-angiogenesis, anti-hypertensive, analgesic, anxiolytic, immunomodulatory, anti-osteoporosis, anti-allergic, anti-aging, and anti-gout activities.
The body systems and health domains with the most preclinical research attention include:
Pharmacokinetic studies have demonstrated the low bioavailability, rapid absorption, and extensive metabolism of scopoletin; these properties may be associated with its poor solubility in aqueous media. Considering the therapeutic activities and the weak oral bioavailability of scopoletin, a large number of its derivatives and pharmaceutical dosages can be designed.
Considering the relatively low plasma concentration detected from scopoletin, the antitumor properties of Artemisia capillaris consequently in part come from capillarisin, capillin, and chlorogenic acids. In other words, the low systemic exposure achieved from oral dosing of scopoletin is a recognized pharmacokinetic limitation that constrains translation of in vitro findings to in vivo therapeutic contexts.
Scopoletin undergoes extensive first-pass metabolism in the liver. Its poor aqueous solubility further limits absorption. Research into pharmaceutical modifications — including hybrid compounds, nanoformulations, and chemical derivatives — is ongoing with the goal of improving oral bioavailability. Isoxazole-based hybrids of scopoletin have been considered as an efficient chemical modification that improved the anticancer activity of scopoletin; the 2-fluorobenzylpyridinium derivative is the most potent tested compound, with an IC50 value of 0.215 ± 0.015 μM, which is significantly ameliorated compared with that of scopoletin.
No established human clinical dosage for isolated scopoletin exists, as there are no approved therapeutic products containing it as a single active ingredient. Dosages reported in the preclinical (animal) literature include:
For human consumers, scopoletin is typically encountered as a constituent of noni juice products or standardized herbal extracts, where scopoletin content is variable and not standardized to a defined dose in most commercial preparations. Scopoletin might be one of the biomarker constituents to use for the quality assessment of noni fruit products used for treating gastro-esophageal inflammatory diseases.
Toxicity research indicates the non-toxicity of scopoletin to most cell types tested to date, suggesting that scopoletin will neither induce treatment-associated mortality nor abnormal performance with the test dose. This assessment reflects the body of in vitro and animal toxicology work and should not be extrapolated to chronic human use in the absence of dedicated clinical safety studies.
While isolated scopoletin shows hepatoprotective properties in animal models, cases of hepatotoxicity have been reported in association with noni juice — one of the most common sources of scopoletin in dietary supplement use. A case of acute liver failure in a patient consuming Herbalife products and noni juice was reported in a peer-reviewed journal. Regulatory agencies have received multiple reports of liver injury associated with noni-containing products. Because noni juice contains many bioactive constituents in addition to scopoletin, it is not currently possible to attribute hepatotoxic events specifically to scopoletin.
As a member of the coumarin chemical class, scopoletin shares structural features with compounds known to have anticoagulant potential (the dicumarol-warfarin lineage). However, scopoletin itself is not a vitamin K antagonist in the manner of warfarin, and its coumarin structure alone does not confer clinically established anticoagulant activity. The potential for additive or pharmacokinetic interactions with anticoagulant medications has not been specifically characterized for scopoletin in controlled human studies.
Scopoletin is an inhibitor of various enzymes, including choline acetyltransferase, acetylcholinesterase, and monoamine oxidase. Monoamine oxidase (MAO) inhibition is a pharmacologically significant property; MAO inhibitors can potentiate the effects of biogenic amines and interact with a wide range of medications, including sympathomimetics, antidepressants, and certain foods. Whether scopoletin achieves in vivo MAO inhibition at doses achievable through dietary supplement consumption has not been established in human studies.
Pharmacokinetic studies have demonstrated the low bioavailability, rapid absorption, and extensive metabolism of scopoletin. This low systemic exposure, while a limitation for therapeutic efficacy, also potentially limits systemic toxic effects from oral consumption of scopoletin-containing plants at typical dietary or supplemental intakes.
Reversing the incubation period of HIV-1 can promote the killing of infected cells, which is crucial for treatment strategies; in HIV-1 latently infected Jurkat T cell lines, scopoletin (2.0 mM) can significantly influence the incubation period of HIV-1 without cytotoxicity in a dose-dependent manner. This finding is preliminary and in vitro only, but is noted as a potential area of future investigation.
There is a significant absence of systematic human clinical safety data for isolated scopoletin. The available safety information derives from in vitro cytotoxicity assays and acute or subacute animal studies. Long-term toxicity studies, reproductive and developmental toxicity assessments, and rigorous genotoxicity profiling for isolated scopoletin in humans remain either unpublished or absent from the peer-reviewed literature. Consumers typically encounter scopoletin as part of complex botanical preparations rather than as a purified compound, making it difficult to attribute specific safety signals to scopoletin per se.
Health conditions that Scopoletin may help support.
Body systems that Scopoletin may help support.
Go back